ClinicaliQ Trial Snapshot
- Atrasentan in Patients With IgA Nephropathy — Active Not Recruiting • Phase III • NCT04573478.
- Atrasentan reduced kidney disease progression in IgA nephropathy patients compared to placebo.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA nephropathy (IgAN) at risk of progressive loss of renal function. Conditions: IgA Nephropathy, Immunoglobulin A Nephropathy Interventions: Atrasentan, Placebo, Zigakibart Lead Sponsor: Novartis Pharmaceuticals Planned Enrollment: 404 participants